1.76 USD
-0.03 (-1.68%)
ChartMill assigns a Buy % Consensus number of 80% to IPHA. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 7.36. This target is 317.97% above the current price.
- IPHA was analyzed by 9 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about IPHA.
- In the previous month the buy percentage consensus was at a similar level.
- IPHA was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-29 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-09-18 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-09-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | SVB Leerink | Maintains | Outperform |
| 2022-09-16 | Citigroup | Maintains | Buy |
| 2022-08-02 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2021-09-17 | SVB Leerink | Maintains | Outperform |
| 2021-09-03 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2021-09-02 | SVB Leerink | Upgrade | Market Perform -> Outperform |
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What is the average price target for INNATE PHARMA SA-SPONS ADR (IPHA) stock?
9 analysts have analysed IPHA and the average price target is 7.36 USD. This implies a price increase of 317.97% is expected in the next year compared to the current price of 1.76.
How do analysts rate INNATE PHARMA SA-SPONS ADR (IPHA)?
The consensus rating for INNATE PHARMA SA-SPONS ADR (IPHA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed INNATE PHARMA SA-SPONS ADR (IPHA)?
The number of analysts covering INNATE PHARMA SA-SPONS ADR (IPHA) is 9.